Vitamin D has been the recommended supplement of choice to promote bone health and immunity, and to prevent complications from serious health issues such as cancer, neurological disease, and long-term COVID-19 symptoms. A new study adds another to the long list of benefits of the sunshine vitamin. Researchers have found that vitamin D supplementation helps prevent major cardiovascular events, including heart disease, in people over the age of 60.
Cardiovascular disease (CVS) is a group of diseases of the heart and blood vessels that kill approximately 17.9 million people each year. Coronary heart disease, rheumatic heart disease, and stroke are some examples of cardiovascular disease.
Earlier study Studies have shown that people with higher blood levels of vitamin D have lower rates of cardiovascular disease. However, once people get adequate levels of vitamin D from sunlight and nutrient-dense foods, the heart benefits from a plateau.
In a new study involving one of the largest research institutes test Researchers evaluated more than 21,000 people over the age of 60 to assess the cardiovascular benefits of monthly vitamin D supplementation in older adults. Participants took one 60,000 IU vitamin D capsule or a placebo at the beginning of each month for up to five years.
However, those with higher than normal calcium levels (hypercalcemia), overactive thyroid (hyperparathyroidism), kidney stones, cartilage (osteomalacia), sarcoidosis (an inflammatory disease) or have People taking 500 IU/day of vitamin D were excluded. Take supplements.
During the trial, 1,336 participants experienced a major cardiovascular event. However, the rate of cardiovascular events was 9 percent lower in the vitamin D group compared with those taking the placebo. The vitamin D group also had a 19 percent lower rate of heart attacks and an 11 percent lower rate of coronary revascularization. The incidence of stroke was not significantly different between the two groups.
The researchers found that the effect was stronger in patients who were on statins or other cardiovascular medications at the start of the trial.
Published by Medicaldaily.com